Intent to Sole Source-University of California San Francisco

The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to the University of California San Francisco (UCSF), Clinical Toxicology and Envirnomental Biomonitoring Laboratory who will conduct investigations and handle evidence related to illicit drugs, including fentanyl and its analogues, perform activities such as collecting, transporting, processing, and analyzing evidence. University of California San Francisco (UCSF) specializes in continuously improving and achieving the lowest achievable detection limit in urine for these analytes of interest (cocaine, benzoylecgonine, methamphetamine, heroin, 6-monoacetylmorphine, hydromorphone, morphine, fentanyl, and norfentanyl) using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Detection levels at other laboratories above these achieved by UCSF would not accurately be able to determine if exposure is occurring. Additionally, UCSF turnaround time is less than one month which is critical for the time sensitive nature of the studies being conducted. The vendor utilizes a proprietary LC-MS/MS technology for illicit drugs and their metabolites detection. This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 10 U.S.C. 2304(c)(1). Interested parties may identify their interest and submit documentation of their capability to respond to the requirement. This notice of intent is not a request for competitive quotations; however, all responses received within five (5) days of the issuance of this notice will be considered by the government. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any response should be emailed to the appropriate point of contact at [email protected] by 11:00 AM on 19 May 2023.